Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers
Status:
Active, not recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, pharmacokinetics and EEG pharmacodynamics of single and
multiple ascending doses of apimostinel in normal human volunteers